<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145404</url>
  </required_header>
  <id_info>
    <org_study_id>NCT-2008-11-01-1015</org_study_id>
    <nct_id>NCT01145404</nct_id>
  </id_info>
  <brief_title>Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer</brief_title>
  <acronym>GastroLap</acronym>
  <official_title>Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Tumor Diseases, Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a&#xD;
      beneficial contribution to current treatment paradigms since preclinical data suggest that&#xD;
      lapatinib alone can decrease TS mRNA and is synergistic with capecitabine in some cell lines,&#xD;
      which may contribute to clinical benefit. The study described in this protocol has been&#xD;
      designed to establish the anti-tumor activity of Lapatinib with or without capecitabine in&#xD;
      the treatment of Her2 overexpressing metastatic gastric- and gastro-esophageal cancer, and to&#xD;
      search for molecular correlates that may be associated with response to this compound.&#xD;
&#xD;
      The majority of patients with metastatic gastric and gastro-esophageal cancer undergo&#xD;
      first-line combined chemotherapy (e.g. platin derivates and fluoropyrimidines, sometimes&#xD;
      combined to a taxane), but the role of second-line chemotherapy has not yet been defined.&#xD;
      Therefore, progression during or shortly after first-line chemotherapy is a medical condition&#xD;
      no standard medical approach exists. The overexpression of EGFR and Her2 in gastric and&#xD;
      gastroesophageal cancer make these indications prime candidate for treatment with the dual&#xD;
      ErbB1/2 tyrosine kinase inhibitor (TKI) Lapatinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Changes of SoC for third line therapy resulting in poor recruitment&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>about 10 month (until progression)</time_frame>
    <description>Objective response rate (ORR, complete and partial remission according to RECIST criteria&#xD;
- all to be confirmed by at least two consecutive tumor response assessments within no shorter than 4 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>about 10 month (until tumor progression)</time_frame>
    <description>Time to tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>about 16 month (6 month after progression)</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of study treatment (for parameters see description)</measure>
    <time_frame>about 10 month (until progression)</time_frame>
    <description>recording of AEs/SAEs, vital signs, ECG, LVEF, physical exams, lab values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>1 month (during screening period)</time_frame>
    <description>the definition of biomarkers that are associated with response or resistance to treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>GastroEsophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.</description>
    <arm_group_label>Arm A: Lapatinib</arm_group_label>
    <other_name>Tyverb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib plus capecitabine</intervention_name>
    <description>Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Tyverb, Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the stomach, including adenocarcinoma of&#xD;
             the gastroesophageal junction and esophagus&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease (according to RECIST criteria)&#xD;
&#xD;
          -  At least one prior chemotherapy for metastatic disease with progression during or no&#xD;
             later than 6 months after last administration of chemotherapy. Chemotherapy must have&#xD;
             contained a platinum compound (cisplatin or oxaliplatin)&#xD;
&#xD;
          -  Her2 overexpression measured by FISH (amplification or increased gene copy number).&#xD;
             Immunohistochemistry (ICH) 3+ can be included in case of an uncertain FISH test.&#xD;
&#xD;
          -  Patient willing to allow for biomarker analyses on his tumor tissue.&#xD;
&#xD;
          -  Written informed consent given prior to any protocol specific procedures according to&#xD;
             the local regulatory requirements&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG-PS) &lt;= 2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function defined by: Hematology: Neutrophils&#xD;
             &gt;1.5x109/L; Platelets &gt;100x109/L; Hemoglobin &gt;8g/dL Hepatic function: Total bilirubin&#xD;
             &lt;=1.5xULN; ASAT (SGOT) and ALAT (SGPT) &lt;= 2.5xULN; Alkaline phosphatase &lt;5xULN. Renal&#xD;
             function: The calculated creatinine clearance should be .60 mL/min&#xD;
&#xD;
          -  Eligibility of patients receiving medications or substances known to affect, or with&#xD;
             the potential to affect the activity or pharmacokinetics of lapatinib will be&#xD;
             determined following review of their use by the local Principal Investigator. A list&#xD;
             of medications and substances known or with the potential to interact with CYP450&#xD;
             isoenzymes is provided in: Cytochrome P-450 Enzymes and Drug metabolism. In: Lacy CF,&#xD;
             Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 8TH ed. Hudson, OH;&#xD;
             LexiComp Inc. 2000: 1364-1371&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Negative pregnancy test (urine or serum) within 28 days prior to randomization for all&#xD;
             women of childbearing potential (has to be verified within 7 days prior to&#xD;
             randomization and during the study according the judgement of the investigator)&#xD;
&#xD;
          -  Willingness to perform double-barrier contraception during study and 6 months after&#xD;
             end of treatment&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous non curatively treated malignant disease other than the current&#xD;
             gastroesophageal cancer with a disease-free survival of less than 5 years&#xD;
&#xD;
          -  History of significant neurological or psychiatric disorders including psychotic&#xD;
             disorders, dementia or seizures that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  History of active Hepatitis B or C or history of an HIV infection&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Treatment within any other clinical trial parallel to the treatment phase of the&#xD;
             current study within 30 days prior to randomisation.&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer drug. Presence of other medication&#xD;
             that may interfere with study treatment or the action of the investigational product&#xD;
             or confuse the assessment of study results&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to lapatinib or to any excipients&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical composition&#xD;
             to capecitabine, fluorouracil or to any excipients&#xD;
&#xD;
          -  Known DPD deficiency&#xD;
&#xD;
          -  Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors&#xD;
&#xD;
          -  Current active hepatic or biliary disease (with exception of patients with Gilbert's&#xD;
             syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease&#xD;
             per investigator assessment)&#xD;
&#xD;
          -  Active cardiac disease, defined as:&#xD;
&#xD;
               -  History of uncontrolled or symptomatic angina&#xD;
&#xD;
               -  History of arrhythmias requiring medications, or clinically significant, with the&#xD;
                  exception of asymptomatic atrial fibrillation requiring anticoagulation&#xD;
&#xD;
                    -  Myocardial infarction &lt; 6 months from randomization&#xD;
&#xD;
                    -  Uncontrolled or symptomatic congestive heart failure (&gt; New York Heart&#xD;
                       Association score 2)&#xD;
&#xD;
                    -  Ejection fraction below the institutional normal limit&#xD;
&#xD;
                    -  Any other cardiac condition, which in the opinion of the treating physician,&#xD;
                       would make this protocol unreasonably hazardous for the patient&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  History of hypersensitivity to the investigational medicinal product or to any drug&#xD;
             with similar chemical structure or to any excipient present in the pharmaceutical form&#xD;
             of the investigational medicinal product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Lordick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Städtisches Klinikum Braunschweig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHARITÉ CAMPUS, VIRCHOW-KLINIKUM, UNIVERSITÄTSMEDIZIN BERLIN, Centrum 14, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld gGmbH, Klinik für Innere Medizin, Hämatologie/Onkologie und Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Uniklinik, Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Bonn gGmbH, Johanniter-Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte, Department of Medical Oncology and Hematology</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen, Klinik für Allgemeine Innere Medizin, Onkologie und Gastroenterologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nord West</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle, Klinik für Innere Medizin IV</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld UG</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCT Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Med. Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Regensburg, Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Her2 Gastro Gastric Esophageal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

